ʻO ka "lāʻau hana mana no ka pohō kaumaha" kokoke e komo i Kina!Ua hōʻoia ʻo Novo Nordisk China e ʻae ʻia ka mana kaumaha o Semaglutide i kēia makahiki

ʻO ka "lāʻau hana mana no ka pohō kaumaha" kokoke e komo i Kina!Ua hōʻoia ʻo Novo Nordisk China e ʻae ʻia ka mana kaumaha o Semaglutide i kēia makahiki
March 8, nūhou e Novo Nordisk manaʻo e hoʻolilo kaumaha version o ka Semaglutide Wegovy e aponoia ma Kina i keia makahiki, ka huahana e lilo i ka hoʻomaka 'ana o ka poe maʻi iho-financed, a aia ka palena i ka helu o nā maʻi.Ma kēia mea, ua hōʻoia ʻo Novo Nordisk Kina i ka nūhou i luna i ka mea hoʻolaha nūhou, "e nānā ana i ka ʻae ʻia i kēia makahiki, i ka hikiwawe e pōmaikaʻi i nā poʻe maʻi obesity Kina."

ʻO Wegovy ka inoa kālepa Pelekane o ka lāʻau lapaʻau GLP-1 Semaglutide i hoʻomohala ʻia e Novo Nordisk no nā hōʻailona hōʻemi kaumaha, i ʻae ʻia ma ke ʻano he lāʻau hoʻēmi kaumaha ma Iune 2021 ma United States.Ua haʻi mua ʻo Tesla CEO Musk i loko o ka pāpaʻi pūnaewele ua hoʻohana ʻo ia i ka lāʻau lapaʻau no ka pohō kaumaha, a ua ʻimi ʻia ʻo ia ma ke ʻano he "lāʻau hana mana no ka pohō kaumaha".

Ma Kina, ua ʻae wale ʻia ka lāʻau lapaʻau ʻo Semaglutide a me ka lāʻau lapaʻau no ka maʻi maʻi maʻi, kahi e ʻae ʻia ai ka inikua simethicone no ke kūʻai ʻana ma Kina i ʻApelila 2021, a ma hope iho e komo i ka palapala hōʻoia olakino olakino ma 2022;Ua ʻae ʻia ʻo Semaglutide waha i Ianuali o kēia makahiki, a ua lilo i ka lāʻau GLP-1 waha mua i ʻae ʻia no ke kūʻai aku ma Kina.

Ma ke ʻano he ʻelele o nā lāʻau lapaʻau GLP-1, ua kūleʻa ʻo Semaglutide.Ua hōʻike ʻia ka hōʻike kālā kālā a Novo Nordisk 2023 ua piʻi ke kūʻai aku ʻo Wegovy i ka 406% a i $ 4.6 biliona, e alakaʻi ana i ke ala GLP-1 honua.Ma muli o kēia, nui nā ʻoihana lāʻau lapaʻau kūloko o Semaglutide biosimilar hoʻomohala lāʻau lapaʻau, akā ʻo ka hapa nui i ka hoʻomaka ʻana o ka lāʻau lapaʻau, e like me Liju Group (000513), Han Yu Pharmaceutical (300199) a me nā hui lāʻau ʻē aʻe he nui i hoʻolaha mua ʻia ʻo Semaglutide o ka hui. ua ʻae ʻia ka injection e hoʻokō i nā hoʻokolohua lapaʻau no nā hōʻailona pili i ka hoʻokele kaumaha.

He mea pono ke olelo aku, me Novo Nordisk i ikeia ma ka inoa o ka "GLP-1 duo" LLY ke paipai nei no hoi i ka papa inoa o GLP-1 kaumaha kaumaha lāʻau Tirzepatide ma Kina, ka mea i manaoia e aponoia domestically.2023 August, LLY Ua hoʻolaha ʻo Kina, e like me ka pūnaewele mana o ka Drug Evaluation Center o ka State Drug Administration.Ua ʻae ʻia ka palapala hoʻopaʻa inoa no Tirzepatide injection no ka hoʻomaikaʻi ʻana i ka hoʻokele kaumaha o ka wā lōʻihi i nā poʻe maʻi me ka momona o nā pākeke a i ʻole ka liʻiliʻi o hoʻokahi comorbidity e pili ana i ke kaumaha ma ke kumu o ka ʻai haʻahaʻa-calorie a me ka hoʻomaʻamaʻa hoʻonui ʻia.

Ua ʻae ʻia ka hōʻailona maʻi diabetes no Tirzepatide ma US i Mei 2022, a ua hāʻawi ka lāʻau lapaʻau i $ 483 miliona i ka loaʻa kālā iā Lilly ma 2022. ʻelua mahina ma lalo o $176 miliona ma ka loaʻa kālā.

Me nā lāʻau lapaʻau ʻo Novo Nordisk a me LLY GLP-1 i manaʻo ʻia e ʻae ʻia no nā hōʻailona pohō kaumaha ma Kina, hiki ke hoʻomaka koke ka hoʻokūkū ma waena o Novo Nordisk a me LLY ma ke ala GLP-1 ma Kina.